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A number of groups have demonstrated signifi cant covariance or correlation structures in PET data sets and have analyzed these structures using a range of techniques (Clark et aI. , 1984; Metter et aI. , 1984; Horwitz et a!., 1986; Yolkow et a!. , 1986; Horwitz, 1991) . Clark et at. (1985) have discussed the potential advantages of using analysis techniques that explicitly allow for heterogeneous regional interactions (e. g. , Q compo nent analysis) because such techniques provide a means of dealing with the likely heterogeneity of disease groups and incorporate a natural model of functional interdependency between brain regions. In addition. Clark et al. (1985) pointed out that re peated-measures analysis of variance (ANOY A) techniques are inappropriate for PET data analyses because they assume specific forms for the regional interdependency that are not consistent with our knowledge of neuroanatomy and neurophysiology. While ANOY As can be modified to account for the violation of such assumptions that typically lead to understated p values, the modified ANOY As have no clear-cut power differences over multivariate ANOV A (MANOV As) methods, which are compu tationally no more difficult to apply (O'Brien and Kaiser, 1985) . However, MANOV As require an as sumption of a common, but possibly heteroge neous, correlation structure for different groups, the violation of this assumption being particularly problematic if the groups are of unequal size (O'Brien and Kaiser, 1985) . The development of the subprofile scaling model (SSM) was motivated by a desire to try to avoid problems of interpretation, which may result from the application of traditional multivariate statistical methods to PET data sets (e.g., the consequences of assuming a specific un derlying correlational structure and group homoge neity), and our wish to incorporate additional fea tures, such as the separation and quantitation of global and regional brain function. SSM is a general form of the two-way factor ANOVA model, which combines "the benefits of a factor analysis decom position of residuals with the ease of interpretation permitted in the analysis of variance" (Y ochmow itz, 1982) . A primary goal of the development of SSM is to identify and model potentially hetero geneous, multidimensional, region-specific varia tion with small numbers of subjects. General goals are (I) to analyze PET data that contain signifi cant, unknown heterogeneities; (2) to obviate the need for a priori assignment of subjects to different groups; (3) to partition the variability (as in ANO V As) for between-subject and between-region ef fects from that of a residual containing a subject region interaction term and measurement error; (4) to provide an explicit cutoff criterion for the num ber of significant, independent covariance struc tures detected, based on calculating the Type I er ror (the probability of falsely identifying an inde pendent pattern of data variation as significant when it is not distinguishable from noise); (5) to provide quantitative global and regional subject measures that may be disease related (i.e. , a func tion of disease progression and severity and a dis criminate function for different brain states); (6) to make explicit the assumptions used to identify re gion-specific effects associated with the above mentioned subject measures; (7) to provide a means of assessing the results of an SSM analysis by test ing the goodness of fit to the original data; (8) to develop a technique for calculating disease-specific covariance patterns utilizing preliminary subject measures from one or more disease and normal groups and independent measures of disease pro gression and severity.
A description of the basic SSM technique has been previously published (Moeller et aI. , 1987) , as 1991 have the results of applying SSM to a range of data sets (Rottenberg et aI. , 1987; Anderson et aI., 1988; Strother et aI. , 1989; Eidelberg et aI., 1990) . Sack eim et ai. (1990) have recently compared SSM to other multivariate data analysis techniques for a large Xe blood flow data base of normals and pa tients with major depressive disorders.
This article provides a fuller description of the SSM technique, corrects several errors that ap peared in the original paper (Moeller et aI. , 1987) , and discusses the potential strengths and weak nesses of this approach with particular reference to underlying assumptions. An extension of the origi nal SSM technique to the generation of disease specific covariance patterns is also discussed.
THEORY

General SSM
The general form of the model has previously been described (Moeller et aI. , 1987) and is given in Eqs. I and 2, and demonstrated graphically in Fig.  1 for rCMR g Ic profiles:
in which SRP ij = 2: SSFIg X GISki + error (2) k where (rCMR g Jc) ij represents the rCMR g Ic for region i of subject j (Y ij in Fig. 2) , GSF j is a global scaling factor, GMP is the group mean profile of GSF nor malized data, and SRP j , the subject residual profile, is that portion of a subject's normalized profile that is not accounted for by GMP. SSFk j is a subject scaling factor that determines the contribution of the kth independent regional covariance pattern (the group invariant subprofile, GISk) to the meta bolic profile of each subject ( Fig. O .
Notations
Vectors in this article are represented in boldface type with the following definitions: GSF GSF� GMP global scaling factor indexed over sub jects a GSF that is independent of the SSFks in the SRP j s group mean profile of the GSF normal ized raw profiles, indexed over regions and common to all subjects subject residual profile indexed over regions for each subject (Eq. 2) subject scaling factors for the kth in- , �,
dependent covariance pattern indexed over subjects disease-specific subject scaling factors calculated from the SSFk values of a combined group analysis group invariant subprofile, i.e., the kth independent covariance pattern in dexed over regions and common to all subjects the raw profile indexed over regions for each subject, e.g., rCMR gIc 10geY j the residual profile indexed over re gions for each subject (Eq. 3)
Model assumptions
The following assumptions were made in devel oping the SSM and an explicit estimation scheme for its parameters:
1. GSF is a multiplicative global scaling factor (Moeller et aI., 1987) that is significantly dif ferent from noise. 2. The subject residual profiles (SRP j s) are small, so that In[1 + (SRPylGMP)J = SRPyi GMP; (Moeller et aI., 1987) , and significantly different from noise.
The error component of the subject residual
profile is assumed to be independently and identically distributed across regions and subjects with zero mean and is independent of GSF and the SSFks values. 4. If the first K principal components are found S# values refer to individual subjects. From left to right, the panels represent subject metabolic profiles; a global scaling factor (GSF); a group mean profile (GMP) defined by the pat tern of mean rCMRg1JGSF across subjects; the subject re sidual profiles (SRPjs), which correspond to the original met abolic profile variation about GMP with the influence of in dividual differences in GSF removed. B: Decomposition of SRPjs into the sum of scaled patterns of regional covariance.
From left to right, the panels represent SRP dS; two sets of scaled covariance patterns (SSFk x GISk). an measurement error. C: Subject scaled pattern of regional covariance illus trated for several subjects in the left panel is composed of subject scaling factors (SSFjs, middle panel) and a regional covariance pattern, the group invariant subprofile (GISk• right panel). For abbreviations see the text.
to be significantly different from noise, where K is much less than the minimum of the num ber of subjects and regions, then (i) these principal components provide a good fit to the residual subject profiles, (ii) none of these principal components has significant outliers in its SSF distribution, and (iii) some of these principal components contain information about systematic differences in brain fu nc tion among subjects and/or groups. 5. The GSF is assumed to be independent of and therefore uncorrelated with the SSFk values so that an unambiguous estimate of GSF, i.e., GSF-L, can be obtained.
Preliminary data transformations-partitioning raw profile variation
The calculation of the residual profile (R j ) follow ing the loge transformation ( Fig. 2) is identical in form to the residual term obtained from partitioning the variance in a one-factor repeated-measures ANOVA (Winer, 1971) . The transformation in cludes two modifications of the raw profiles de signed to remove the between-region and between subject variability. The between-region variation is defined by (Vi. -VJ, l which represents variation in the regional mean values about their grand mean. Similarly, the between-subject variation is defined ing an SSM analysis. The highlighted three dimensional boxes identify the input-the raw profiles, V I s-and the output: the subprofile scaling factors, SSFks; GSF-L, a global scaling factor that is uncorrelated with the SSFks; the regional covariance patterns defined by the group invariant subprofiles, GISks. Shaded cells represent intermediate computational steps, cy lindrical for intermediate transformations, and octagonal for multivariate procedures. Two dimensional boxes represent intermediate re sults from multivariate procedures. Following a loge transformation the raw profiles have be tween-subject and between-region sources of variation removed (Theory) to produce the re siduals, R I . A peA is applied to the intersubject covariance matrix between residual profiles (calculated across regions). The SSFk distribu tions for independent sources of variation from the residual appear as eigenvectors. The princi pal component scores associated with each eigenvector represent relative GISk• (GISk/ GMP);, patterns with an unknown offset, (GISJGMPl.. A cutoff criterion is used to identify the K principal components that are signifi cantly different from noise (Theory), and these are used in all subsequent computations. All computations and results following the dotted lines are dependent on the assumption that the global scaling factor is uncorrelated with the K significant SSFks. The output of the peA just preceding the dotted lines is independent of any global scaling effect in the raw profiles, hence this assumption. The left-hand path from the SSFk output of the peA represents one multi variate means of obtaining the uncorrelated GSF -1. . The output from this multivariate analysis provides estimates of the (GISJGMP). offset and GMP needed to obtain GISk by the right-hand path from the principal components scores. For abbreviations see the text.
SSFk is the iIIb. by (Vj -VJ. which represents the variation in the subjects' mean values about the grand mean. Sub traction of these two sources of variability from the total variation term (Vij -VJ produces the residual profile of Fig. 2 . Under the small signal approxima tion of Assumption 2, together with Eq. 1, this re sidual is given by
Note that the re sidual is similar but not identical to the subject residual profile (Eq. 2). In practice these transformations are equivalent to subtracting Vi. from V ij for each subject's loge-transformed profile and then forming the covariance matrix between subjects calculated across regions (i.e., an inter sub-
GISk is the pattern of regional covariation with subject scaling factor SSFk ject covariance matrix similar to the type used in Q component analyses; see Clark et al ., 1985) . Note that the number of rows and columns of this covari ance matrix is defined by the number of subjects.
Removing the between-region term is equivalent to removing the group mean profile (GMP) as a po tentially confounding term from the intersubject co variance matrix. Not removing the GMP term would have the effe ct of redistributing variance and changing the patterns of the principal components from the principal components analysis (PCA; Fig.  2 ) . The GMP does not reflect differences between subjects and/or groups because by definition it is common to all subjects within the analysis. There fore , the inclusion of GMP reduces the chance that the first fe w eigenvectors will reflect group dependent differences in brain fu nction.
Assumptions 3 and 5 ensure that the sources of data variation across subjects for each region are independent. Since the variance of the sum of inde-pendent random variables is equal to the sum of the variances, from Eqs. 1 and 2 we have
where Var; is the variance across subjects for region i. Eq. 4 demonstrates the partitioning of the loge transformed raw profiles' variation into a number of independent sources: one global , K regional , and error.
PCA output
The PCA (Anderson, 1984) applied to the inter subject covariance matrix of the residual profiles produces principal components with three parts: (1) an eigenvector that contains an SSF j distribution for one independent source of variation; (2) an eigen value that defines the variance accounted for in the residual profile by its associated eigenvector; (3) principal components scores, which are calculated from the eigenvector and the residual profiles and which define the pattern of spatial covariation as sociated with each eigenvector's SSF j values. Prin cipal components from a PCA are ordered in terms of variance accounted for from the largest to the smallest eigenvalue. Because of the removal of be tween-subject effects in the initial transformations, all three elements of the PCA output are indepen dent of any global scaling effect in the raw profiles. The relationship between an eigenvector, its asso ciated principal components scores, and the resid ual profiles is given by Eqs. 4 and 5 ( Fig. 2) :
where ek is the kth eigenvalue.
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The initial transformations of the raw profiles cause the SSFk and relative GISk, (GISk/GMP), out puts of the PCA to appear with offsets. In the case of the eigenvectors' SSF distributions, this has no effect since L j SSF k j = O. The offset subtracted from the relative GIS pattern in the principal components scores has a significant effect on the spatial infor-mation available from the SSM analysis. These off set patterns contain no region-specific information about variation in the model's subject residual pro files because the unknown size of the offset , (GISk/GMP)., determines which regions have zero or near-zero pattern weights; i.e., it is unknown which regions are significant nonzero components of the relative GISk pattern. Nonetheless, the offset patterns do contain relative regional information: These spatial patterns, together with their SSFs, provide information about subject or group differ ences for all regional ratios that can be formed within individual subjects' raw profiles (Yj; Fig. 2 ) . Consider the ratio of any pair of regions (a,b) from a raw profile. From Eq. 1, with the small signal approximation of Assumption 2, the loge of this ra tio is given by
Consider the difference between the mean values for this ratio , calculated across two groups of sub jects, p(.) and q(.). From Eq. 7 we have
All the information necessary to calculate the right hand side of Eq. 8 is available in the output of the PCA of the residual profiles ( Fig. 2) .
Selecting significant principal components
Specification of the Type I error is accomplished by applying Assumption 3, that measurement error is independently and identically distributed with re spect to subjects and regions, to the principal com ponents eigenvalues. A sufficient statistic for iden tifying significant eigenvectors is the maximum like lihood statistic used to test" equality of the smallest eigenvalues" (Anderson, 1984) . Together with As sumption 4(i) , the maximum likelihood statistic will tend to restrict the number of significant principal components so that only the first few from the peA will be identified as being different from noise.
Identifiability of the global scaling factor
Consider a general form of the SSM equations where GSF is correlated with the SSFk values. In loge space this general form of the GSF may be expressed as the combination of a component that is independent of (not correlated) with the SSFk val ues, i.e., GSF-1, and a linear combination of the SSFk values. This relationship is given by Eq. 9:
By substituting Eq. 9 into Eq. 1, we obtain
using the small signal approximation of Assumption 2, which includes the Uk values. The error term has been dropped since it has a mean of zero across subjects and regions. Based on the PET data alone, Eq. 10 cannot be distinguished from Eq. 1 using the post hoc parameter estimation procedures outlined in Fig. 2 or any other procedures that we are aware of. Therefore, there is an identifiability problem be tween the general form of the global scaling factor (that is correlated with SSFk values) and GISk re gional covariance patterns without an offset. The lack of region-specific information in GISk patterns with an unknown offset has been discussed above.
If SSM represents a reasonable model of PET data variation, then it may be impossible to extract un ambiguous estimates of the GISk regional covari ance patterns on the basis of the PET data set alone. The use of global metabolic rate (GMR) to nor malize raw profiles implicitly assumes a model of data variation similar to Eq. 1 with GMR used as an estimate of GSF. From Eq. 1, again assuming the small signal approximation, GMR may be ex pressed as
where 13 = (GMPJ. There is no reason to assume that the exponential term in Eq. 11 is zero , except by chance for individual subjects. Therefore, con sider the consequences of normalizing by a global scaling factor estimate that is in error by exponen tial terms such as those in Eqs. 9 and 10 . For the explicit example of GMR, normalizing Eq. 1 with 1991 Eq. 11 and using the small signal approximation, we obtain
GMPi + -7 SSFkiGISki -OkGMPJ (12) where Ok = (GISkIGMP) .. Equation 12 demon strates that normalization with GMR as an estimate of the global scaling factor creates a new set of pro files where the underlying regional covariance pat terns have gained offsets they should not have. The goal of normalization with GMR was to remove a region-independent global scaling effect, yet the normalized profiles are likely to have a quite differ ent pattern of regional variation from the original profiles. For example, regions that had no variation in the original profiles (GISki = 0) may now vary appreciably and vice versa. Even though the Ok val ues that define the correlation between the original raw profiles' SSFk and GMR are assumed to be small (Assumption 2) , there is no such restriction on GMPi; thus, the 0kGMPi term of Eq. 12 could rea sonably be of the same size or larger than the GISki patterns themselves. Therefore, normalization by GMR may lead to large distortions of the original raw profiles' covariance structure and the loss of region-specific information.
Post hoc estimation of GSF and GIS Assumption 5 satisfies Goal 6 listed in the intro ductory section. The assumption is required to re solve the basic identifiability problem outlined above as regards the offsets needed to determine the region-specific covariance patterns, the GISk terms, and the global scaling factor. With the as sumption of independence between the GSF and the SSFk, the post hoc estimation scheme outlined in Fig. 2 provides explicit values for the GISk terms and a region-independent GSF, i.e., GSF-1. Note that Assumption 5 is required only to enable the post hoc calculation of the GISk and GSF-1 from the output of the PCA. Assumption 5 is not required to quantify subject variation (SSFk) or to obtain infor mation about changes in regional ratios (from the principal components scores) , because the residual profiles and the output of the PCA are independent of any global scaling effect in the raw profiles.
Disease-specific patterns
In a clinical application of SSM to a combined group of patients and normal controls, the SSFk val ues can be used to define a one-dimensional mea sure of disease progression and severity with an associated regional covariance pattern. The dis-ease-specific scaling factor (SSFox) is constructed for the combined group of patients and controls such that (1) a high correlation is obtained in the patient group between SSFox and a clinical , neuro physiological, or neuropsychological measure of disease progression or severity and (2) the variation of patient SSFox values is maximized while simul taneously the variation of control subject SSFox values is minimized. Ideally, such a subject classi fication procedure would terminate with the SSFox values reduced to a fixed value for all members of the control group, while the patient SSFox values would provide a very high correlation with an inde pendent, non-PET measure of disease progression or severity. Figure 3 illustrates different hypothetical rela tionships between measures of disease severity and the SUbject/patient scaling factor, SSFox. Each of the four curves, A-D, represents a different class of patient SSFox values. In Fig. 3 the mean value of the control group is assigned a value of zero on the ordinate; the variability in the estimate of what should ideally be a constant normal value is de picted as variable shading about zero. Curve A rep resents the ideal relationship in which discrimina tion between the disease population and the normal popUlation is nearly perfect; early detection is pos sible, and the large negative slope of the curve per mits continuous classification of the different de grees of disease severity based on patient scaling factors. In contrast, Curve B produces early detec tion but a poorer patient classification compared with Curve A, because it decreases only slightly with disease progression. Curve C illustrates how a disease-specific pattern of regional covariance might not provide early detection, while permitting a high degree of discriminability and sensitivity to disease severity at later stages of the disease. Fi nally , Curve D illustrates an example of early de tection without patient control discriminability through the midrange of disease severity and pro gression.
METHODS
Details of [ 18 F]fluorodeoxyglucose PET data collection and organization into rCMR g lc profiles of 28 regions each for the data sets considered in this article have been pre viously reported: para neoplastic cerebellar degeneration (Anderson et aI., 1988) , acquired immune deficiency syn drome (AIDS) dementia complex (Rottenberg et aI., 1987) , and Parkinson's disease (Eidelberg et aI., 1990) . All data sets were analyzed using the SSM methodology outlined below. SSM computations are subdivided into two main stages (Fig. 2): (1) a quantification of indepen dent sources of subject residual profile variation and the associated principal components scores, which represent Each of the four curves defines different relationships between neurobehavioral indexes and metabolic descriptors of disease severity: A, good group dis crimination, early disease detection, and sensitivity to dis ease progression; B, good discrimination, early disease de tection, but poor sensitivity to disease progression; C, good sensitivity to disease progression and poor group discrimi nation and disease detection until mid-to late-stage disease; 0, poor group discrimination but early disease detection and sensitivity to disease progression for mid-to late-stage dis ease severity. offset regional covariance patterns; followed by (2) selec tion of significant principal components and a post hoc determination of the regional covariance pattern offsets and associated global scaling factors.
Data transformations and peA
As a first step in estimating subject effects, two trans formations are applied to region-of-interest (ROI) meta bolic activity: (1) the data are loge transformed; (2) the mean profile of transformed metabolic activity, calcu lated for the combined groups, is subtracted from each subject's transformed metabolic profile. As a second step, the covariance values are computed between the transformed raw profiles (across regions) and the inter subject covariance matrix is submitted to a PCA. The output includes the eigenvectors (SSFks) and their asso ciated eigenvalues and principal components scores (Fig.  2) . Scaling is imposed to ensure that the sum of the squares of the SSFks for each eigenvector equals the as sociated eigenvalue, while the sum of the squares of the regional values of the principal components scores equals 1.0. In the PCA results, the percPfltage of the subject variance accounted for (% V AF) by each principal com ponent equals the ratio of the respective eigenvalue to the sum of eigenvalues.
Selecting significant principal components and estimating GSF and GIS
A cutoff criterion assigns all but the principal compo nents with the largest eigenvalues to the component of SRP variation considered to be measurement error. A Type I error rate is chosen and the test "for the equality of smallest eigenvalues" is applied (Anderson, 1984) to the PCA eigenvalues. First, all eigenvalues are included in the calculation of the statistic. If a significant result is obtained, the largest eigenvalue is excluded and the sta tistic recalculated. Eigenvalues are successively excluded with retesting until an insignificant result is obtained. The cutoff is therefore defined as the smallest number of eigenvalues for which the next maximum likelihood sta tistic is not significant for a prescribed Type I error rate.
This typically defines a small number (K) of significant principal components. For all groups analyzed, the Type I error rate was set with p = 0. 01.
Global scaling factor values are calculated using As sumption 5, that GSF is independently distributed with respect to the SSFk terms and measurement error, i. e. , GSF l-. The mean over subjects of the loge-transformed raw profiles, (loge Y)., is predicted from the K subject SSFk values using the standard multiple linear regression model (Fig. 2) . The GSFf terms are assumed to be equal to the residual values about the predicted regression line for each subject's SSF j values. The offset of the relative GISk pattern from each principal component score is obtained from the coefficient of each SSFk in the regres sion and used to obtain the relative GISk pattern. Finally, GISk is obtained by normalizing each raw profile by GSF l-, averaging across all subjects to obtain the group mean profile, and multiplying by GMP to obtain the GISk regional covariance pattern. At this point the preliminary SSM analysis has been completed and estimates are available for all model parameters. GMP and SSFk x GISk are scaled to represent the units of the raw profiles using the exp[(logeGMP).] value available from the intercept of the linear regression performed between (loge Y). and the SSFk terms.
Testing the model fit
The validity of Assumptions 1, 2, 3, and 4(i) is tested by examining the fit of the model to the original data with and without GSF l -normalization ( Fig. 4) . Assumption 4(ii) is tested by visual examination of the SSFk distribu tions for outliers. Assumption 4(iii) is examined by com paring the SSM results to independent neurophysiologi cal, neuropsychological, and/or neuroanatomical evi dence. In particular, subject pattern variation recorded in the SSFks is tested for group discrimination and corre lated with independent measures of disease progression and severity.
As a test of Assumptions 1-4(i), the ability of the model parameter estimates to predict the AIDS patient data was examined. Each loge-transformed raw profile was nor malized by subtracting 10geGSF/ . Then a mUltiple linear regression of each region against the K significant SSFks was performed for both loge-transformed un normalized and normalized raw profiles. The %V AF was recorded for each ROI regression and plotted as a function of re gion number (Fig. 4 ). In addition, estimates of the ratio of the 10geGSF l -variance and the SSF1, ••• , SSFk variance to the error component variance were obtained. This was made possible by assuming that these three components have additive variance, a property that follows from As sumptions 3 and 5, which state that all three components are independent (Eq. 4). Assumptions 3 and 5 are tested by observing whether or not the two %V AF plots for normalized and unnormalized raw profiles differ only by an additive constant (Theory, Eq. 4, and Appendix) . Assumptions 1, 2, and 4(i) are tested by observing whether or not the % V AF for most regions of the nor malized data implies a ratio of the SSFk variance to error variance of >2-3 (this requires %VAF values >65-75%; see Eq. A2). In addition, to demonstrate the existence of a significant global scaling factor and its successful re moval, the %VAF for most regions from the unnormal ized data should lie sufficiently below the normalized data line that the ratio of 10geGSF l -variance to error variance is also >2-3 (Eqs. A2 and A3).
Disease-specific patterns
A disease-specific scaling factor is constructed from the K SSFks that pass the principal components cutoff criterion. A canonical correlational analysis (Mardia et al., 1979) is applied jointly to the SSFks and a set of in dependent neurobehavioral measures. Scores on the in dependent measures are extended to normal controls by uniformly assigning a score of zero; a group identifier variable is included in the correlational analysis on the "side" of the independent measures to provide one pa rameter for the offset of the true normal SSFox values relative to the mean patient values. The output of the canonical correlational analysis is the SSFox and a linear composite of disease severity scores. With a canonical correlation near unity, the variance of the control SSFox values is a small fraction of the variance of the patient scaling factors, and the patient SSFox values are highly correlated with the independent neurobehavioral mea sures.
RESULTS
The results of an SSM analysis are reported for 12 neurologic patients suffering from the AIDS demen tia complex (13 scans, I repeat) combined with 18 normal volunteers. These results have been re ported in detail elsewhere and will be only summa rized here (Moeller et aI., 1987; Rottenberg et aI., 1987) . Two eigenvectors (SSFl and SSF2) were re tained from the PCA based on a p = 0.01 signifi cance level and the cutoff criterion defined by the maximum likelihood statistic (Methods). Together SSFl and SSF2 accounted for 55% of the variance in the residual profiles. The subject values of GSF1were computed on the basis of the two SSFks, using the post hoc estimation procedure outlined in Fig. 2 .
In Fig. 4 the % V AF for predicting both 10geGSF1--normalized and unnormalized loge tra.w:>tmmed raw profl\e va\ues usi.ng SSFl and SSF2, is plotted for each of 28 ROIs for the AIDS patient data. Jointly, SSFl and SSF2 account for >70% of the subject variation in GSF1--normalized rCMR g lc in 22/26 ROIs, pairs of which are homologous loca tions in the two hemispheres; variation in the 4 re maining ROIs with homologous locations, plus sub ject variation in two midline subcortical ROIs, was accounted for by noise alone in terms of the model assumptions (%VAF by SSFl and SSF2 was <15% in unnormalized rCMR g 1c)' In these AIDS data, the two curves of % V AF appear nearly parallel across the 28 ROIs, suggesting that the variance of 10geGSF1-, the SSFks, and error terms is additive and that the error term is approximately identically distributed across regions (Theory, Eq. 4, and Ap pendix). The dotted lines with p values at different levels of % V AF indicate the probability of achiev ing greater than or equal to those % V AF levels for the 13 AIDS patients by chance. For most regions the %VAF for normalized data lies in the 75-90% range, which implies a ratio of SSFl plus SSF2 vari-ance to error variance of 3-9 (Eq. A2). The median incremental difference between the % V AF for un normalized metabolism and the % V AF for normal ized metabolism is 40% . This difference in %V AF together with the 3-9 range for the ratio of SSFl 2 variance to error variance implies a ratio �f 10geGSF1-variance to error variance of �5-8 (Eqs. A2 and A3). Overall, these findings suggest that subject variance additivity is well satisfied and that Assumptions 1-4(i) are reasonable for this data set.
Disease-specific patterns
Disease-specific patient scaling factors are pre sented in Figs. 5-7 for three patient groups suffering from distinct neurological diseases: paraneoplastic cerebellar degeneration (Anderson et aI., 1988) , AIDS dementia complex (Rottenberg et aI., 1987) , and Parkinson's disease (Eidelberg et aI., 1990) . In all three combined group analyses (normals plus pa tients), the cutoff criterion based on the maximum likelihood statistic with p = 0.01 resulted in just two significant principal components. No outliers were observed for the SSF distributions associated (Anderson et aI., 1988 Fig. 3 . Inset: Associated regional co variance pattern with the same region distribution along the abscissa as in Fig. 4 . Assuming an independent global scal ing factor, GSF�, the disease-specific regional covariance pattern does not contain the cerebellum as the predominant component (the left-most homologous pair on the profile). The greatest disease-specific change in regional ratios with disease progression is seen between the maximum upward deflection of the operculum and the maximum downward deflection of the posterior temporal cortex. Fig. 3 . The filled circles represent the patient who was studied twice. Inset: Associated regional covariance pattern with the same region distribution along the abscissa as in Fig. 4 . Assuming an independent global scaling factor, GSF"-, the disease-specific regional covariance pattern identifies the basal ganglia (with the maximum upward deflection) as the predominant component. The greatest disease-specific change in regional ratios with disease progression is seen between the basal ganglia and the hippocampus (the maxi mum downward deflection). On the basis of the positive SS Fox values for early-stage disease and the negative values for late-stage disease, the trend with disease progression repre sents a possible early hypermetabolism that diminishes, fail ing back into the normal range, and eventually becomes hy pometabolism at end-stage disease.
with these principal components for any of the dis ease groups. An R 2 value of >85% (p < 0. 001) be tween the extracted disease-specific SSFDX and the non-PET independent measures was required be fore SSFDX was considered to be disease specific. This level was achieved for all three patient groups.
DISCUSSION
The SSM was developed to satisfy a number of data analytic goals that did not appear to be ade quately served by traditional multivariate tech niques. The discussion of these goals will fo llow the outline in the introductory section, which in turn follows the steps of an SSM analysis outlined In Fig. 2 .
A priori analysis assumptions
The desire to be able to analyze unknown, het erogeneous covariance structures and to identify J Cereb Blood Flow Metab, Vol. 11, Suppl. 1, 1991 Disease-specific subject scaling factors (SSFox; ordi nate) are plotted against a measure of unsigned motor asym metry (abscissa) based on left-right differences in the clinical ratings for limb rigidity and/or tremor for Parkinson's disease (PD) (Eidelberg et aI., 1990) . The dashed lines demarcate the minimum and maximum SSFox values for the normal control group; the ordinate units are the standard deviation of the normal SSFox estimates. The patient SSFox values demon strate a curve that is similar to the initial portion of Curve D of Fig. 3 . A large value for motor asymmetry indicates that motor function is more severely impaired on one side of the body than on the other: either left more than right, or vice versa. A value of zero indicates either no asymmetry in im pairment or normal functioning, i.e., no impairment of either side. Note that motor asymmetry is inversely related to clin ical indexes of disease progression .. Inset: Associated re gional covariance pattern with the same region distribution along the abscissa as in Fig. 4 . Assuming an independent global scaling factor, GSF"-, the disease-specific regional co variance pattern identifies midbrain, basal ganglia, posterior temporal cortex, calcarine cortex, and cuneus (maximum downward deflections from left to right) as strongly nega tively correlated with the operculum (maximum upward de flection). This pattern indicates that a ratio of the three cor tical regions to the operculum could provide a sensitive in dex of early parkinsonism.
and model multiple sources of independent varia tion is satisfied by performing a PCA of the residual profiles' intersubject covariance matrix. Heteroge neity in SSM terms means a set of independent, spatially nonuniform GISks. When there is no sys tematic structure in the residual profiles, the data set is uninteresting, for both subject groups repre sent random profile variation about a common GMP. When the groups are individually, relatively homogeneous but have different group mean pro files, the residual profiles of the combined group analysis will have a covariance structure deter mined by the difference between the individual group mean profiles. If this situation can be as sumed in advance, an ANOV A or MANOV A may be a more appropriate analysis procedure if we are interested primarily in testing whether or not there are two significant groups and possibly some inter action effects. Similarly, if it is known in advance that the groups have only a common heterogeneous covariance structure , then a MANOV A may be ap propriate for detecting group differences and signif icant interaction effects. However, the SSM analysis is performed blind to any potential group classifications because of the difficulties of knowing what assumptions about group structure are reasonable in any given PET data set, particularly for potentially heterogeneous disease groups. This procedure has the benefit of ensuring that the SSF j s within each eigenvector from the PCA are uncorrelated. With the additional assumption that the SSF j s are individually normally distributed, they may subsequently be analyzed us ing traditional multivariate techniques to test for significant group effects . While statistical power may be lost in an SSM analysis as a result of not incorporating assumptions about the covariance structure and group assignments, in our experience this has not appeared to be the case for a range of disease groups Anderson et al., 1988; Eidelberg et al., 1990) . SSM may retain statistical power in analyzing these data sets be cause their principal components contain regional covariance patterns (GISk) common to the groups, while the groups are quite well separated on the basis of their SSF j s. In such cases, combining groups may be advantageous for the detection and estimation of significant principal components be cause of the greater number of independent samples (subjects) used and the potentially greater range of subject scaling compared to within groups. The ex tent to which SSM may lose power in highly con trolled experiments where accurate a priori infor mation about group structure is available is pres ently being investigated.
Partitioning regional variation
A choice must be made as to which components of the raw profiles to incorporate into the intersub ject covariance matrix. Partitioning profile variation (Theory) into between-subject and between-region components and a residual containing a subject region interaction term plus error highlights the choice between (1) focusing on subject similarities by forming the intersubject covariance matrix from the raw profiles, treating the between-region term as the component of interest and considering all of the residual as an error term, or (1) focusing on the subject differences b)' removing the between-region variation from the proflles before forming the inter subject covariance matrix, treating the subject-region interaction term as the component of inter est. Note that the between-subject effects are re moved by fo rming the intersubject covariance matrix.
The first choice was made by Clark et al. (1985) in their analysis of the homogeneity of a group of 15 normals undergoing electrical shocks to the right fo rearm. The SSM analysis makes the second choice to focus on the subject-region interaction term as described in Theory. The difference be tween these two analysis approaches stems from somewhat different views of the intermediate goals in PET data analysis. In terms of SSM parameters, Clark et al. (1985) focused on the extent to which GMP represents a (possibly scaled) version of each subject's raw profile using intersubject correlations as a measure of similarity. Our SSM analysis seeks to quantitatively model subject residual differences about the common GMP as spatial covariance pat terns. Note that Eq. 8 demonstrates that informa tion on the difference between group mean regional ratios is in the residual term of the combined groups. The discovery of disease-related SSFs for a range of disease groups (Rottenberg et aI. , 1987; Anderson et al ., 1988; Strother et aI. , 1989; Eidel berg et aI ., 1990; Sackeim et al., 1990) and the ex traction of the disease-specific patterns illustrated in Figs. 5-7 demonstrate that for such heteroge neous groups quantitative modeling of the subject region interaction term can be useful. Note that to be disease related the principal components' SSFks must provide some degree of group discrimination and for disease be correlated significantly with in dependent measures of disease severity and pro gression.
Selecting significant principal components
No assignment of components as significant vari ation and error is made until the output of the PCA is obtained. The use of a test for the "equality of smallest eigenvalues" (Theory and Methods) to gether with Assumption 4(i) ensures that the eigen vectors retained as significant will account for a large part of the residual profile variance. This ap proach to principal components significance is quite conservative in that it tends to emphasize the vari ation of large regional networks over isolated re gional effe cts unless the experimental paradigm successfully reduces differences due to regional networks while selectively enhancing differences due to a few isolated regional effects , e.g., the sub traction techniques of and It is important to recognize that significant prin cipal components will not necessarily reflect the fu nctional brain differences and/or group effects of primary experimental interest. Uncontrolled physi cal, physiological, and fu nctional processes may create principal components that are not disease re lated or group specific. Worsley et al . (1989) have described a regional pattern effe ct that could result in a significant regional covariance pattern that may have no relationship to different functional groups. However, the multidimensional sorting into inde pendent sources of variation afforded by the PCA will assist in separating out some such effects as separate principal components. Other confounding variables that are highly correlated with the exper imental effects of intere st may produce composite principal components that fail to separate the two sources of variation. For example, an age and a disease effe ct might be confounded in a single prin cipal component, but the availability of the eigen vector's SSF j s allows such principal components to at least be identified if measures of disease severity and age are both correlated with the SSF j s. In all the groups studied to date, we have found a disease related principal component as one of the first two significant components produced by the PCA. Therefore, our results suggest that Assumption 4(iii) may often be valid.
Testing individual subjects
An SSM analysis fo cuses primarily on the infor mation available from the subject measures, the SSFks, because of the identifiability problem for GSF and GISks (Theory and Discussion below). In particular, it is possible to estimate SSFks for indi vidual subjects (using Eq . 6) so that they may be added one at a time to the PCA output of an initial SSM analysis. For example, a single subject's SSF k j could be tested with respect to a previously gener ated SSFk distribution that reflects disease severity . It must be assumed that inclusion of the new subject would not have significantly changed the Vi.' term used to remove between-region effects in the initial analysis (Theory).
Unidentifiability of region-specific effects and global scaling factor
Part of the original motivation for developing the SSM was to explicitly separate and describe global and regional aspects of brain fu nction. However, it has become apparent that achieving such separation is dependent on whether GSF is uncorrelated with the SSFks. This identifiability constraint determines whether or not region-specific effects that are new and unambiguously defined can be discovered using only PET data sets derived from measures of brain fu nction such as CMR g lc and CBF (Theory).
Imposing Assumption 5, which defines GSF as mates of GMR are used in an attempt to minimize the l)kS (Eq. 12). The results of PET analyses of normalized data can always be used in a purely exploratory sense to generate region-specific hypotheses based on re gional effects found to be statistically significant, by assuming that the ukS are zero (Eqs. 9 and 10), as is done in SSM analyses. In fact, it can be reasonably argued that given the sources of error in the acqui sition and analysis of PET data sets, this should be the usual application of all statistical analyses. However, because of the identifiability problem, replication of a finding in additional PET data sets represents a weak test of any such hypotheses. In general , strong independent evidence will be needed to confirm or deny such a region-specific PET hypothesis. If there is compelling independent evidence that a particular region should exhibit a significant functional effect, and such an effect is found in the PET data, then this may be used to constrain the size of any offset that may be associ ated with the underlying spatial covariance pat terns.
For example , independent evidence might be used to set a given GISki to zero for all k because it is known that there will be minimal fu nctional vari ation in that region. Fixing one such region would have the effect of defining the region-specific ef fects of all other regions in the GISks. This demon strates a potential advantage of having a model that generates significant spatial patterns of regional co variation, such as GISks. Independent evidence supporting the discovery of a significant effect in one region may be used to establish the likely sig nificance of spatial effe cts in other regions because these effects are known to be linked and satisfy similar conditions on their GIS values. When apply ing post hoc region identification using traditional statistical procedures, it is not clear how to utilize independent information for one region to establish the validity of other significant regional effects. This is particularly true when the possibility of mul tidimensional regional variations with both positive and negative covariances is considered.
GSF-i vs. GMR
Finally, consider the problem of how to choose an estimate of the global scaling effect. If GSF is known to be uncorrelated with the included SSFks (Assumption 5) , then provided the other SSM as sumptions hold, GSF-i calculated using the post hoc estimation procedures of Fig. 2 will generally be a better estimate of the global effects than GMR. This is true because all techniques for estimating GMR (that the authors are aware of) incorporate all mea-sured ROI gray matter values; unless the subject residual profiles contain no significant covariance structures, i. e. , GSF-i = GMR, then GMR will al ways be correlated with the SSFks (Eq. 11).
In the general situation where the form of the global scaling effect is not known, it is impossible to say which is the better estimate, GSF-i or GMR. GSF-i will in general be different from GMR if there is any significant structure in the subject residual profiles. A reasonable means of proceeding would be to repeat an analysis using both forms of normal ization and to compare the results. If the results are different, there is evidence that the normalization technique may be an important, potentially con founding effe ct and that this issue requires further investigation.
Testing SSM
To establish the validity of Assumptions 1-4(i) and the parameter estimation scheme outlined in Methods and Fig. 2 , the ability of the model esti mates to predict the original data is tested. A good fit is considered to have been achieved when the % V AF of the error term contributed by all the non significant eigenvectors is much less than the % V AF accounted for by the significant eigenvec tors across the majority of regions. In addition, we require that the variance of the global scaling fa ctor removed by normalization be significantly larger than the variance of the error estimate. This is the situation demonstrated in Fig. 4 for the AIDS pa tient data. Regions that have a %V AF by the error term that is larger than the % V AF by the significant eigenvectors should be examined independently to see if there is one additional eigenvector that ac counts for the majority of the %VAF in the error term and might therefore represent an isolated re gional effect. Note that disease-related principal components might still be obtained when Assump tion 4(i) is not satisfied; however, imposing As sumption 4(i) makes it unlikely that any potentially important sources of profile variation are being overlooked.
Disease-specific SSFs
The ability to extract disease-specific SSFDX dis tributions from only two significant eigenvectors in each disease group provides evidence that Assump tion 4(iii) is reasonable for the data sets analyzed. However, several of the disease processes are clearly multidimensional as demonstrated by the discrimination plots for AIDS patients in Rotten berg et al. (1987) and for paraneoplastic cerebellar degeneration patients in Anderson et a1. (1988) . Fig  ure 6 (AIDS patients) demonstrates the discrimina tion problems that can be encountered at different stages of disease with a one-dimensional descrip tion of a multidimensional disease process. The generation of multidimensional subject scaling fac tors that are independent of the estimation prob lems of normalization and regional localization is a key feature of the SSM analysis approach.
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, For unnormalized, loge-transformed raw profiles, the corresponding relationship is given by lOO'X ' %VAF(K SSFkS) = x . + c +' 1 (A3) I where c = Var(logeGSF1-)IVar;(error) . This ratio, c , is a constant independent of region since the error is assumed to be the same for every region (Assump tion 3). Therefore, the difference between unnor malized %VAF (by the SSFks) and GSF1normalized %V AF is controlled by this single ratio of the global scaling factor variation to the noise variation. The difference between Eqs. A2 and A3 is a max imum for Xi = Vc+l and is V lowly decrvsing on either side in the interval (0.5 c + 1, 2.0 c + 1). For the AIDS patient results with c = 6, this implies that if Var;(error) is the same over all regions, then the % V AF by the SSFks in the normalized profiles can range from �50-90%, and the difference be tween the equations will remain approximately con stant. This is the result seen in Fig. 4 where the plots of the regional % V AF for the normalized and J Cereb Blood Flow Metab, Vol. II. Suppl. 1, 1991 unnormalized profiles are approximately the same distance apart for the majority of the regions.
